Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Cerevel Therapeutics Hldg Inc (CERE)

Cerevel Therapeutics Hldg Inc (CERE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? Motley Fool - Mon May 20, 9:58AM CDT

Revenue growth during what should be a disastrous patent cliff is encouraging.

CERE : 42.90 (+0.47%)
ABBV : 172.32 (+0.69%)
Is AbbVie Stock a Buy Now? Motley Fool - Thu Feb 22, 4:15AM CST

Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.

ABBV : 172.32 (+0.69%)
CERE : 42.90 (+0.47%)
Is AbbVie Stock a Buy Now? Motley Fool - Sun Jan 7, 6:33AM CST

The company is grappling with losing Humira's patent protection in 2023.

IMGN : 31.23 (unch)
CERE : 42.90 (+0.47%)
ABBV : 172.32 (+0.69%)
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December Motley Fool - Sun Dec 10, 2023

These companies offer above-average income streams that should continue rising.

SRC : 42.31 (-1.56%)
CERE : 42.90 (+0.47%)
O : 57.58 (-0.26%)
BEPC : 28.05 (-2.09%)
BEP : 24.06 (-1.35%)
ABBV : 172.32 (+0.69%)
VZ : 41.62 (-1.07%)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? Motley Fool - Sun Dec 10, 2023

The big drugmaker went on a holiday shopping spree.

AGN.AX : 0.860 (+2.99%)
ABBV : 172.32 (+0.69%)
IMGN : 31.23 (unch)
CERE : 42.90 (+0.47%)
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? Motley Fool - Fri Dec 8, 2023

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

ABBV : 172.32 (+0.69%)
CERE : 42.90 (+0.47%)
IMGN : 31.23 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE PR Newswire - Fri Aug 18, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 42.90 (+0.47%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 42.90 (+0.47%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE PR Newswire - Fri Aug 4, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 42.90 (+0.47%)
Why Shares of Cerevel Therapeutics Are Dropping Wednesday Motley Fool - Wed Aug 2, 2023

The company reported second-quarter earnings.

CERE : 42.90 (+0.47%)

Barchart Exclusives

Why One Analyst Says Palantir Stock is a Sell Ahead of Earnings Barchart - 9 minutes ago
Despite Palantir's impressive 66% surge this year, Mizuho downgraded the stock to 'Underperform' due to concerns over high valuation and limited earnings visibility. With mixed analyst ratings and the Q2 earnings report approaching, investors are advised to tread carefully and prepare for potential volatility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot